Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy

AIDS

Volumn 28, Issue 2, 2014, Pages 201-208

  Torres Cornejo, Almudena ^a   BenMarzouk Hidalgo, Omar J ^a   Gutiérrez Valencia, Alicia ^a   Pérez Romero, Pilar ^a   Martín Peña, Reyes ^a   Ruiz Valderas, Rosa ^a   Viciana, Pompeyo ^a   Lopez Cortes, Luis F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

HIV reservoir; HIV 1 therapy; Monotherapy; Ritonavir boosted darunavir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; COHORT STUDIES; DNA, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROVIRUSES; REAL-TIME POLYMERASE CHAIN REACTION; RITONAVIR; SULFONAMIDES; VIRAL LOAD; VIREMIA;

EID: 84892367593     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000060     Document Type: Article

References (34)

1. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load
2. Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-230.
3. Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929-939.
4. Cahn P, Montaner J, Junod P, Patterson P, Krolewiecki A, Andrade-Villanueva J, et al. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. PLoS One 2011; 6:e23726.
5. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234-240.
6. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24:2347-2354.
7. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.
8. Meynard JL, Bouteloup V, Landman R, Bonnard P, Baillat V, Cabie A, et al. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 2010; 65:2436-2444.
9. Nunes EP, Santini de Oliveira M, Mercon M, Zajdenverg R, Faulhaber JC, Pilotto JH, et al. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials 2009; 10:368-374.
10. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-9.
11. Valantin MA, Lambert-Niclot S, Flandre P, Morand-Joubert L, Cabie A, Meynard JL, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother 2012; 67:691-695.
12. Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011; 204:1211-1216.
13. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C, Kerdraon R, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term nonprogressors. AIDS 2008; 22:1880-1882.
14. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94:12574-12579.
15. Hatzakis AE, Touloumi G, Pantazis N, Anastassopoulou CG, Katsarou O, Karafoulidou A, et al. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 2004; 18:2261-2267.
16. Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 2002; 185:1409-1416.
17. Bruisten SM, Reiss P, Loeliger AE, van Swieten P, Schuurman R, Boucher CA, et al. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1998; 14:1053-1058.
18. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(R) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869-8873.
19. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15:665-673.
20. Verhofstede C, Reniers S, Van Wanzeele F, Plum J. Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 1994; 8:1421-1427.
21. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cellassociated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000; 14:2805-2812.
22. Avettand-Fenoel V, Flandre P, Chaix ML, Ghosn J, Delaugerre C, Raffi F, et al. Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. J Antimicrob Chemother 2010; 65:1005-1007.
23. Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, et al. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One 2012; 7:e41390.
24. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19:156-164.
25. PrezistaTM. J-CL. Full prescribing information.http://www.emea. europa.eu/docs/en-GB/document-library/EPAR-Product-In formation/human/000707/ WC500041756.pdf. European Medicine Agency [Accessed on 1-8-2013].
26. Raymaekers M, Smets R, Maes B, Cartuyvels R. Checklist for optimization and validation of real-time PCR assays. J Clin Lab Anal 2009; 23:145-151.
27. Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 2012; 25: 17-25.
28. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
29. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med 2004; 10:525-531.
30. Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 2003; 4:137-143.
31. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4R T cells. Nat Med 2003; 9:727-728.
32. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
33. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007; 45:381-390.
34. Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, et al. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003; 187:38-46.